Form 4: Kronos Bio Executive Granted Stock Options

Charles Y. Lin, Chief Scientific Officer of Kronos Bio, Inc., was granted employee stock options for 72,900 shares on October 15, 2024.

Summary

• Charles Y. Lin, the Chief Scientific Officer of Kronos Bio, Inc., was granted employee stock options.
• The transaction occurred on October 15, 2024.
• Lin received options for 72,900 shares of common stock with an exercise price of $0.96 per share.
• The options vest in equal monthly installments over a four-year period, starting October 15, 2024.
• The options expire on October 14, 2034.
• Following the transaction, Lin directly owns 72,900 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, which are generally viewed favorably as aligning management and shareholder interests.

Positives

• The granting of stock options to the Chief Scientific Officer aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives. This grant aligns with standard compensation practices in the sector.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry, often used to align management's interests with shareholder value creation.
• Companies like Amgen, Gilead Sciences, and Biogen routinely use stock options as part of their compensation strategy.
• The vesting schedule of 4 years is also typical, encouraging long-term commitment from the executive.
• The number of shares granted and the exercise price would be benchmarked against similar-sized biotech companies and the executive's role and responsibilities.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the executive's performance leads to company growth.
• It incentivizes the Chief Scientific Officer to contribute to the company's success.

Key Dates